Clinical Trials Browser

Turcot syndrome, Squamous Cell Carcinoma of Head and Neck, Carcinoma, Non-Small-Cell Lung, Melanoma, Endometrial Neoplasms, Small Cell Lung Carcinoma, Triple Negative Breast Neoplasms

NCT07144384 2026-02-13

Intratumoral Injection of Standard Universal Donor Expanded Natural Killer Cells and TGF-beta Imprinted Natural Killer Cells for the Treatment of Skin Squamous Cell Carcinoma and Basal Cell Carcinoma

Phase EARLY_PHASE1 Recruiting

40 enrolled

Dermatologic

Carcinoma, Basal Cell

NCT05358938 2026-02-06

Exercise to Boost Response to Checkpoint Blockade Immunotherapy

Phase EARLY_PHASE1 Active not recruiting

22 enrolled

Dermatologic

Melanoma, Motor Activity, Skin Neoplasms, Carcinoma, Merkel Cell

NCT03543969 2026-02-05

Adaptive BRAF-MEK Inhibitor Therapy for Advanced BRAF Mutant Melanoma

Phase EARLY_PHASE1 Active not recruiting

14 enrolled

Dermatologic

Melanoma, Skin Neoplasms

NCT07389525 2026-02-05

Immune Checkpoint Inhibitor (ICI)-Drug-Drug Interaction (DDI) Study

Phase EARLY_PHASE1 Not yet recruiting

80 enrolled

DermatologicGastrointestinalSarcoma

Gastrointestinal Neoplasms, Melanoma, Sarcoma, Urogenital Neoplasms

Clinical Trials

RP1 in Primary Melanoma to Reduce the Risk of Sentinel Lymph Node Metastasis

Pilot Study of Nivolumab w/Ipilimumab or Relatlimab in Surgically Resectable Melanoma Brain Metastases

A Randomized Controlled Trial of Topical 5% Niacinamide for Skin Cancer Prevention in Transplant Recipients

Adaptive Therapy of Vismodegib in Advanced Basal Cell Carcinoma

CivaDerm(TM) Surface Therapy Pilot Study

Pilot Trial of Supplemental Vitamin A and Nicotinamide

Imiquimod and Pembrolizumab in Treating Patients With Stage IIIB-IV Melanoma

Adjuvant Therapy Based on Pathologic Response After Neoadjuvant Encorafenib Binimetinib in Melanoma

177Lu-anti-PD-L1 sdAb in Metastatic Solid Tumors

Intratumoral Injection of Standard Universal Donor Expanded Natural Killer Cells and TGF-beta Imprinted Natural Killer Cells for the Treatment of Skin Squamous Cell Carcinoma and Basal Cell Carcinoma

Exercise to Boost Response to Checkpoint Blockade Immunotherapy

Adaptive BRAF-MEK Inhibitor Therapy for Advanced BRAF Mutant Melanoma

Immune Checkpoint Inhibitor (ICI)-Drug-Drug Interaction (DDI) Study